Parametrica Management’s Century Therapeutics IPSC Stock Holding History

Parametrica Management’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$62.9K	Hold	27,840	–	–	0.07%	19
2025 Q4	$27.7K	Hold	27,840	–	–	0.04%	21
2025 Q3	$13.9K	Hold	27,840	–	–	0.02%	23
2025 Q2	$15.6K	Hold	27,840	–	–	0.03%	27
2025 Q1	$13.3K	Hold	27,840	–	–	0.02%	23
2024 Q4	$28.1K	Hold	27,840	–	–	0.04%	65
2024 Q3	$47.6K	Hold	27,840	–	–	0.06%	62
2024 Q2	$71K	Hold	27,840	–	–	0.09%	20
2024 Q1	$116K	Hold	27,840	–	–	0.17%	22
2023 Q4	$92.4K	Hold	27,840	–	–	0.15%	26
2023 Q3	$55.7K	Hold	27,840	–	–	0.09%	29
2023 Q2	$88K	Hold	27,840	–	–	0.17%	26
2023 Q1	$96.6K	Hold	27,840	–	–	0.17%	24
2022 Q4	$143K	Hold	27,840	–	–	0.29%	35
2022 Q3	$275K	Sell	27,840 -1,015	-4%	-$10.7K	0.56%	40
2022 Q2	$241K	Buy	+28,855	New	+$283K	0.26%	103
2022 Q1	–	Sell	-28,855	Closed	-$459K	–	241
2021 Q4	$459K	Buy	28,855 +100	+0.3%	+$1.88K	0.46%	36
2021 Q3	$723K	Buy	+28,755	New	+$778K	0.54%	39

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Parametrica Management's IPSC Position: Q1 2026 in Review

Parametrica Management held its Century Therapeutics (IPSC) position steady in Q1 2026 at 27,840 shares worth $62.9K. The position accounts for 0.07% of the portfolio, ranked #19.

Parametrica Management first reported a position in IPSC in Q3 2021 and has held it in 18 quarters since. The position peaked at $723K in Q3 2021. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

Parametrica Management held 27,840 shares of Century Therapeutics worth $62.9K as of Q1 2026.
Parametrica Management left its Century Therapeutics share count unchanged in Q1 2026.
Century Therapeutics made up 0.07% of Parametrica Management's portfolio in Q1 2026, its #19 holding.
Parametrica Management first reported a position in Century Therapeutics in Q3 2021 and has held it in 18 quarters since.
Parametrica Management's Century Therapeutics position peaked at $723K in Q3 2021.
72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Parametrica Management's 13F filing for Q1 2026, filed 11 May 2026.